Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
Omidenepag isopropyl ophthalmic solution provides an intraocular pressure-lowering benefit that is noninferior to that obtained with latanoprost eye drops in the treatment of patients with ocular hypertension or primary open-angle glaucoma, according to the results of a phase III study in Japan.
A triple fixed combination of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution provides superior intraocular pressure (IOP)-lowering effects compared with a dual fixed combination of brimonidine 0.2%/timolol 0.5% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), according to the results of a phase III study.
New drug applications approved by US FDA as of 01 - 15 March 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A novel incentive strategy which rewards patients who are compliant to their medications significantly improves adherence rates, thus providing a potential cost-effective adherence intervention, the SIGMA* study shows.
Once-daily dosing of the Rho kinase inhibitor netarsudil is not inferior to twice-daily timolol in terms of lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, while having tolerable adverse events, according to the results of the phase III ROCKET-4 trial.
A new study from the UK has suggested that patients recently diagnosed with ocular hypertension or open angle glaucoma (OAG) could derive greater benefit from undergoing selective laser trabeculoplasty (SLT) rather than being treated with intraocular pressure-reducing eye drops.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Patients newly diagnosed with glaucoma are highly likely to report depressive symptoms, with risk factors including young age and female sex, among others, a study has found. Depressive symptomatology appears to decrease considerably 1 year after treatment but remains elevated in patients with impaired vision-related quality of life.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.